Health

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation…

17 hours ago
Idorsia publishes the resolutions for the upcoming bondholder meetingIdorsia publishes the resolutions for the upcoming bondholder meeting

Idorsia publishes the resolutions for the upcoming bondholder meeting

Ad hoc announcement pursuant to Art. 53 LR The updated invitation to the bondholder meeting – scheduled for February 25,…

17 hours ago
Illuccix Approved in the United KingdomIlluccix Approved in the United Kingdom

Illuccix Approved in the United Kingdom

February 12, 2025 16:38 ET  | Source: Telix Pharmaceuticals Limited MELBOURNE, Australia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals…

17 hours ago
Jade Biosciences to Participate in TD Cowens 45th Annual Health Care Conference and Jefferies Biotech on the Beach SummitJade Biosciences to Participate in TD Cowens 45th Annual Health Care Conference and Jefferies Biotech on the Beach Summit

Jade Biosciences to Participate in TD Cowens 45th Annual Health Care Conference and Jefferies Biotech on the Beach Summit

February 12, 2025 16:30 ET  | Source: Jade Biosciences VANCOUVER, British Columbia and SAN FRANCISCO, Feb. 12, 2025 (GLOBE NEWSWIRE)…

17 hours ago
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of DirectorsSerina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing…

17 hours ago
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PNUPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on…

2 days ago
Lighthouse Autism Center Announces Expansion of ABA Services in NebraskaLighthouse Autism Center Announces Expansion of ABA Services in Nebraska

Lighthouse Autism Center Announces Expansion of ABA Services in Nebraska

Leading ABA Provider Set to Open Newest Location in Lincoln, NE. February 11, 2025 20:00 ET  | Source: Lighthouse Autism…

2 days ago
Microbot Medical Closes $13 Million Registered Direct OfferingMicrobot Medical Closes $13 Million Registered Direct Offering

Microbot Medical Closes $13 Million Registered Direct Offering

February 11, 2025 18:15 ET  | Source: Microbot Medical Inc. BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical…

2 days ago
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

February 11, 2025 17:30 ET  | Source: AnaptysBio, Inc. SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:…

2 days ago
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PNSpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on…

2 days ago